The World Market for Antidepressants, 2006

Questions: Discounts, Updates etc.

Pages: 112

Price (Single): £1,499

Price (Departmental): £2,999

Price (Company): £4,999

Publication Date: 2005-12-09

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

In 2004 total world revenues for branded antidepressant drugs was worth over $13bn, but with only ten drugs on the market. However, nine out of these ten drugs faces a loss of patent in the period 2006-2010.

Dr Tom Newton, pharmaceutical analyst with visiongain and author of The World Market for Antidepressants, 2006, predicts that the world market will crash producing revenues in 2010 of only $7bn. This is a loss of almost 50% of total revenues. The world antidepressants market is in serious trouble. Also the pipeline is lackluster with no drugs likely to be launched that will halt this massive revenue loss. Even the recent launch of Cymbalta from Eli Lilly will not save this market. However, the antidepression market is not the only market to face high patent loss and a very strong generic threat.

The World Market for Antidepressants, 2006 from visiongain thoroughly analyses this market and includes an indepth view of the generic threat with US based generic revenues as an indicator of the way the rest of the world market is headed.

This report assess the new pipeline drugs and identifies the potential blockbuster. Also, an examination of the global market by country indicates distortions in the market and possible new areas of expansion. Overall visiongain's The World Market for Antidepressants, 2006 will discuss the most important aspects of this declining market and possible ways of reducing revenue loss.


Why you Should Buy this Report

This 110 page, 25,000 word report has over 50 table and figures, news, insights, the very latest developments and the most up to date revenue information and forecasts to 2010. This report is a vital addition to gaining an understanding of this dynamic and turbulent market and will give your company the edge over your competitors. You can not afford to be without this latest report from visiongain.

Table of Contents

  • 1. Executive Summary
  • 1.1  Aims And Scope of Antidepressants, 2006
  • 2.  Introduction

      • 2.1  The Global Cost of Depression
      • 2.2 Overview of the Global Antidepressant Market
      • 2.2  The Threat of Generics

  • 3. Disease Background and Treatment Options

      • 3.1  What Is Depression?
      • 3.2  Different Types Of Depression
        • 3.2.1 Major Depressive Disorder (MDD)
        • 3.2.2 Dysthymia
        • 3.2.3 Bipolar Disorder Is Not Depression
        • 3.2.4 Other Types Of Depression
      • 3.3  Causes Of Depression
      • 3.4  Age, Sex and Depressive Disorders
        • 3.4.1 Depression In Women
        • 3.4.2 Depression In Men
        • 3.4.3 Depression In The Elderly
      • 3.5  The Receptor Hypothesis Of Depression
        • 3.5.1 Serotonin
        • 3.5.2 Norepinephrine (Noradrenaline)
        • 3.5.3 Dopamine
        • 3.5.4 Targets For Drug Development
      • 3.6  Anxiety
      • 3.7  Drug Therapies For Depression
        • 3.7.1 Monoamine Oxidase Inhibitors (Maois)
        • 3.7.2 Tricyclic Antidepressants (TCAs)
        • 3.7.3 Selective Serotonin Re-Uptake Inhibitors
        • 3.7.4 Selective Serotonin and Norepinephrine Re-Uptake Inhibitors
        • 3.7.5 Selective Catecholamine Reuptake Inhibitors
      • 3.8  Leading Drugs In The Antidepressant Market and Their Mode Of Action

  • 4. World Antidepressant Market, 2005-2010

      • 4.1 World Revenue Forecast For Leading Antidepressants
      • 4.2  Market Share by Drug
      • 4.3  Patent Issues and Generic Encroachment
      • 4.4  More Sophisticated Marketing is Required to Drive the Market
        • 4.4.1 Regulatory Restraints Limit Marketing Options
        • 4.4.2 Tapping the Untapped - Can Antidepressant Uptake      be Increased by Marketing?
        • 4.4.3 New Indications and Off-Label Use Can Extend an Antidepressant's Lifetime
        • 4.4.4 Compliance is a Major Concern
        • 4.4.5 New Formulations Will Provide a Small Amount of Protection from Generics
        • 4.4.6 Pricing
      • 4.5 The Psychology of Drug Prescription
      • 4.6  SSRIs Dominate But Will Lose their Majority Market Share by 2010
      • 4.7  SSNRIs Will Increase Their Market Share
      • 4.8  Other Modes of Action Should Hold their Market Share But May Lose Out to New Treatments
      • 4.9  Individual Forecasts For SSRIs
        • 4.9.1 Zoloft (Pfizer)
        • 4.9.2 Paxil/Seroxat (GSk)
        • 4.9.3 Lexapro And Celexa (Lundbeck A/S and Forest Laboratories)
        • 4.9.4 Prozac (Lilly)
        • 4.9.5 Luvox (Astellas Pharma)
      • 4.10 Effexor Is Well-Established But Faces a Challenge from Cymbalta
        • 4.10.1 Effexor (Wyeth)
        • 4.10.2 Cymbalta (Lilly)
      • 4.11  Other Classes of Antidepressants
        • 4.11.1 Wellbutrin (GSK)
        • 4.11.2 Remeron (Azko Nobel)
      • 4.12 The Antidepressant Market Will Become Extremely Dynamic Because of the Next Generation of Therapies

  • 5.  The Global Market by Country

      • 5.1  United States
      • 5.2  Japan - A Model for Market Expansion
      • 5.3 Europe
      • 5.4  Potential Markets Will Be Hard to Find

  • 6. Threats and Unmet Needs in the Antidepressant Market

      • 6.1  SWOT Analysis of the Antidepressant Market
      • 6.2  Reduction in Side Effects
      • 6.3 Treatment Resistant Depression (TRD) is a Large Untapped Market
      • 6.4  The Lag Period Before Drug Effectiveness is a Restraint on Compliance
      • 6.5  Alternative Treatments For Depression Present Possible Threats and Emphasize Unmet Needs
        • 6.5.1 St. John's Wort
        • 6.5.2 Electroconvulsive Therapy (ECT)
        • 6.5.3 Psychotherapy
      • 6.6  Summary: New Antidepressants Need to Reduce the Lag Time

  • 7.  Pipeline Drugs

      • 7.1 Triple Uptake Inhibitors - the Next Step From SSNRIs
        • 7.1.1 (R)-Sibutramine Metabolite (Sepracor)
        • 7.1.2 DOV 216,303 and DOV 21,947 (Merck)
        • 7.1.3 NS2359 and Radafaxine
      • 7.2  5HT Antagonists and Agonists
        • 7.2.1 Gepirone ER
        • 7.2.2 Vilazodone
        • 7.2.3 PRX-00023
      • 7.3  Neurokinin Receptor Antagonists
        • 7.3.1 Saredutant Potentially Offers a New Approach
        • 7.3.2 GSK Has Three NK Receptor Antagonists in Development For Depression
      • 7.4  CRF Antagonists
      • 7.5  Other Approaches May Still Yield Results
        • 7.5.1 Valdoxan
        • 7.5.2 Beta Adrenergic Receptor Agonists (SR 58878)
        • 7.5.3 Monoamine Oxidase Inhibitors
      • 7.6  A Varied And Competitive Pipeline For New Antidepressants
      • 7.7 Are Unmet Needs Likely To Be Met Soon? Valdoxin And Saradutant Are The Most Promising Candidates

  • 8. Conclusion: The Global Antidepressant Market will see a Severe Drop in Revenue

      • 8.1 The Antidepressant Market Faces an Uncertain Future

  • TABLES
  • Table 1.1 Leading Drugs in the Antidepressant Market, 2005
  • Table 2.1  Main Causes of Disability in Disability Adjusted Life Years (DALY) for Adults 15-59, 2002
  • Table 3.1 Top Ten Antidepressants in the World and their Mode of Action, 2005
  • Table 4.1  World Revenues ($m) for Antidepressant Drugs, 2003-2010
  • Table 4.2 Patent Expiry for Antidepressants and Selected Formulations, 2005
  • Table 4.3  FDA Approved Indications for Antidepressants, 2005
  • Table 4.4  Patent Expiry for Extended Release Formulations (US patents), 2005
  • Table 4.5 World Zoloft Revenues ($m), 2003-2010
  • Table 4.6 World Paxil Revenues ($m), 2003-2010
  • Table 4.7  World Celexa Revenues ($m), 2003-2010
  • Table 4.8  World Lexapro Revenues ($m), 2003-2010
  • Table 4.9  World Prozac Revenues ($m), 2003-2010
  • Table 4.10  World Luvox Revenues ($m), 2003-2010
  • Table 4.11 World Effexor Revenues ($m), 2003-2010
  • Table 4.12  World Cymbalta Revenues ($m), 2003-2010
  • Table 4.13  World Wellbutrin Revenues ($m), 2003-2010
  • Table 4.14  World Remeron Revenues ($m), 2003-2010
  • Table 5.1 US Revenues ($m) for Antidepressants, 2002-2004
  • Table 5.2 US Prescription Numbers (m) for Antidepressants, 2002-2004
  • Table 5.3 Percentage of Prescriptions for Generic and Branded Antidepressants (US) 2002-2004
  • Table 5.4 Average Cost ($/unit) of Antidepressant Prescriptions (US), 2004
  • Table 5.5 Generic Prescriptions (US) for Leading Antidepressants, 2004
  • Table 5.6 Generic Revenues (US) for Leading Antidepressants, 2004
  • Table 6.1 Major Antidepressant Drug Classes and Common Side Effects, 2005
  • Table 7.1 Triple Uptake Inhibitors in the Developmental Pipeline, 2005
  • Table 7.2 5HT Agonists in the Developmental Pipeline, 2005
  • Table 7.3 Neurokinin Receptor Antagonists in the Developmental Pipeline, 2005
  • Table 7.4 CRF Receptor Antagonists in the Developmental Pipeline, 2005
  • Table 7.5 Antidepressants with Other Modes of Action in the Developmental Pipeline, 2005
  • Table 8.1 The Substantial Influence of Patent Loss on the Antidepressant Market, 2005
  • FIGURES

  • Figure 4.1 Total World Revenues for Antidepressants, 2003-2010
  • Figure 4.2 World Revenues for Leading Antidepressants, 2004 and 2010
  • Figure 4.3  Market Share (%) for Antidepressants, 2004
  • Figure 4.4  Market Share (%) for Antidepressants, 2010
  • Figure 4.5  Cost of Antidepressants, 2005
  • Figure 4.6  Price Comparison of Branded and Generic Antidepressants, 2005
  • Figure 4.7 World Market Share (%) by Drug Class, 2004
  • Figure 4.8  World Market Share (%) by Drug Class, 2010
  • Figure 4.9  World Revenues ($m) for Zoloft, 2003-2010
  • Figure 4.10 World Revenues ($m) for Paxil, 2003-2010
  • Figure 4.11 World Revenues ($m) for Celexa and Lexapro, 2003-2010
  • Figure 4.12 World Revenues ($m) for Prozac, 2003-2010
  • Figure 4.13 World Revenues ($m) for Luvox, 2003-2010
  • Figure 4.14 World Revenues ($m) for Effexor, 2003-2010
  • Figure 4.15 World Revenues ($m) for Cymbalta, 2003-2010
  • Figure 4.16 World Revenues ($m) for Wellbutrin, 2003-2010
  • Figure 4.17 World Revenues ($m) for Remeron, 2003-2010
  • Figure 4.18 World Market Share (%) by Company, 2004
  • Figure 4.19 World Market Share (%) by Company, 2010
  • Figure 5.1 World Revenues ($m) for Antidepressant by Country/Region, 2004
  • Figure 5.2 Revenues ($m) for US Antidepressants, 2004
  • Figure 5.3 Prescriptions for US Branded and Generic Antidepressants, 2002-2004
  • Figure 5.4 US Prescription Trends for Antidepressants, 2002-2004
  • Figure 5.5 Percentage of US Prescriptions for Generic and Branded Antidepressants, 2002
  • Figure 5.6 Percentage of US Prescriptions for Generic and Branded Antidepressants, 2004
  • Figure 5.7 Average Cost ($/unit) of Antidepressants, 2004
  • Figure 5.8 Willingness to Seek Help for Mental Health  Disorders in Europe
  • Figure 5.9 World Revenue ($m) for Antidepressant by Country in Europe, 2004
  • Figure 6.1 A SWOT Chart for the Antidepressant Market, 2005
  • Figure 8.1 Antidepressant Market in Relation to Major Patent Losses, 2004-2010

    • Other users found this report page using the following search terms: depression Antidepressants market antidepressant antidepressants leading top share valdoxin uk valdoxan 10

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.